"Rhabdomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Descriptor ID |
D012208
|
| MeSH Number(s) |
C04.557.450.590.550.660 C04.557.450.795.550.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rhabdomyosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Rhabdomyosarcoma".
This graph shows the total number of publications written about "Rhabdomyosarcoma" by people in this website by year, and whether "Rhabdomyosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 4 | 2 | 6 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 5 | 0 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 5 | 0 | 5 |
| 2021 | 11 | 0 | 11 |
| 2022 | 10 | 0 | 10 |
| 2023 | 13 | 0 | 13 |
| 2024 | 13 | 0 | 13 |
| 2025 | 14 | 0 | 14 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rhabdomyosarcoma" by people in Profiles.
-
TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma. Oncogene. 2026 May; 45(18):1714-1728.
-
Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431. Pediatr Blood Cancer. 2026 Jun; 73(6):e70293.
-
Do skeletal muscle bulk and density affect survival outcome in pediatric patients with rhabdomyosarcoma? Radiol Med. 2026 Apr; 131(4):693-696.
-
Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternational Soft Tissue saRcoma ConsorTium (INSTRuCT). Cancer Med. 2026 Mar; 15(3):e71524.
-
Clinicopathologic and Molecular Genetic Features of Spindle Cell Rhabdomyosarcoma Harboring ZFP64::NCOA2/3 Fusions: A Series of 14 Cases. Mod Pathol. 2025 Dec; 38(12):100906.
-
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatr Blood Cancer. 2025 Dec; 72(12):e32046.
-
Single site metastatic rhabdomyosarcoma: An INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) pooled analysis. Eur J Cancer. 2025 Oct 16; 229:115793.
-
Minimally invasive approach to retroperitoneal lymph node dissection in pediatric paratesticular rhabdomyosarcoma: A multi-institutional case series. J Pediatr Urol. 2026 Feb; 22(1):105543.
-
The International Soft Tissue Sarcoma Consortium: The baseline analysis of rhabdomyosarcoma data. Cancer. 2025 Jul 15; 131(14):e35974.
-
Extremity rhabdomyosarcoma in children, adolescents and young adults: A report from Children's Oncology Group trials. Cancer. 2025 Jun 15; 131(12):e35929.